Drug intelligence / Profile preview

DBXO-4

Development stage: Unknown
Lead developer: Deck Bio
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

DBXO-4 is a multi-peptide-major histocompatibility complex (multi-pMHC) targeted T cell engager (dbTCE) being developed by Deck Bio for the treatment of solid tumors. It is designed to target multiple cancer-specific peptide-MHC complexes presented by HLA-A*01:01 on tumor cells while simultaneously engaging CD3 on T cells to recruit and activate them for tumor cell killing. By targeting multiple independent pMHCs, DBXO-4 aims to overcome tumor heterogeneity and antigen escape, which are common resistance mechanisms in solid tumors. The candidate is currently in the discovery phase of development.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on DBXO-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBXO-4.

Explore the full profile